News Zai Lab Limited

Stocks

ZLAB

US98887Q1040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 00:00:00 01/08/2026 +04			5-day change	1st Jan Change
18.27 ^USD	+0.33%		-4.94%	+3.57%

07-29	Asian Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading	MT
06-30	Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing	MT

All News

Mentions Relevance

07-22	Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026	BU
06-30	Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing	MT
06-17	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan in Pulmonary Neuroendocrine Carcinomas	AQ
06-16	Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug	MT
06-16	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas	BU
06-09	Zai Lab Says China Approves Tivdak for Cervical Cancer Treatment	MT
06-09	Zai Lab Receives China NMPA Approval For TIVDAK For Treatment Of Recurrent Or Metastatic Cervical Cancer	CI
06-09	Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer	BU
05-22	Zai Lab President, COO Josh Smiley to Depart	MT
05-22	Zai Lab Ousts COO Josh Smiley	MT
05-22	Zai Lab Announces Changes to Senior Leadership Team	BU
05-22	Zai Lab Limited Announces Departure of Josh Smiley as President and COO, Effective May 22, 2026	CI
05-20	Zai Lab Insider Sold Shares Worth $1,986,875, According to a Recent SEC Filing	MT
05-16	Zai Lab Insider Sold Shares Worth $2,003,044, According to a Recent SEC Filing	MT
05-11	Zai Lab Limited Receives FDA Fast Track Designation for Zocilurtatug Pelitecan for Treatment of Extrapulmonary Neuroendocrine Carcinomas	CI
05-11	Zai Lab Receives FDA's Fast Track Designation for Zoci in Extrapulmonary Neuroendocrine Carcinomas	MT
05-11	Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)	BU
05-08	Zai Lab's Net Loss Widens in Q1	MT
05-08	Zai Lab Limited, Q1 2026 Earnings Call, May 07, 2026
05-07	Zai Lab Q1 Loss Widens, Revenue Falls	MT
05-07	Earnings Flash (ZLAB) Zai Lab Limited Reports Q1 Revenue $99.6M, vs. FactSet Est of $108.4M	MT
05-07	Earnings Flash (ZLAB) Zai Lab Limited Reports Q1 Loss of $0.46 per ADS, vs. FactSet Est of $-0.54	MT
05-07	Zai Lab Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates	BU
04-22	Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026	BU